Core Viewpoint - Gyre Therapeutics, Inc. announced that its subsidiary in China, Gyre Pharmaceuticals, has completed a Pre-New Drug Application meeting with the Center for Drug Evaluation regarding Hydronidone, a first-in-class anti-fibrotic therapy for chronic hepatitis B-associated liver fibrosis [1][10]. Group 1: Regulatory Progress - Gyre Pharmaceuticals and the CDE reached a consensus that existing Phase 3 clinical data for Hydronidone support a conditional approval NDA submission for treating chronic hepatitis B-associated liver fibrosis, including early cirrhosis [2][10]. - The CDE indicated that Hydronidone qualifies for inclusion in China's Priority Review and Approval Program for Innovative Drugs, pending formal filing and regulatory review [2][10]. - Hydronidone received Breakthrough Therapy Designation from the NMPA in March 2021, recognizing its potential to address a serious condition with significant unmet medical need [3]. Group 2: Clinical Trial Results - Gyre reported that in its Phase 3 trial, 52.85% of treated patients achieved ≥1-stage fibrosis regression at Week 52, compared to 29.84% in the placebo group (p=0.0002) [4]. - The trial also met a key secondary endpoint by demonstrating improvement in liver inflammation without fibrosis progression and showed a favorable safety profile [4]. Group 3: Future Plans - The company plans to conduct an additional confirmatory Phase 3c trial in China to evaluate liver-related clinical outcomes, supporting the potential conversion from conditional approval to regular approval [5]. - Gyre expects to submit an NDA for conditional approval of Hydronidone in the first half of 2026, subject to final data readiness and regulatory procedures [5][10]. Group 4: Market Opportunity - Chronic hepatitis B-associated liver fibrosis represents a significant unmet medical need in China, with an estimated 60–70 million people infected with hepatitis B virus, and approximately 2.6 million diagnosed with clinically significant liver fibrosis [11].

Core Insights - Gyre Therapeutics reported a net income of $5.9 million for Q3 2025 and $11.2 million for the nine months ended September 30, 2025, reflecting improved commercial execution and cost control [1][7][15] - The company revised its full-year revenue guidance to $115-118 million, down from $118-128 million, due to delays in the rollout of Etorel® and uncertainties in government procurement [1][18] Financial Performance - Q3 2025 revenue reached $30.6 million, a 20% increase year-over-year, driven by growth in ETUARY®, Etorel®, and Contiva® sales [7][16] - For the nine months ended September 30, 2025, total revenue was $79.4 million, slightly above the $77.9 million reported for the same period in 2024 [15][16] - Basic EPS improved to $0.04 for Q3 2025, compared to $0.01 in Q3 2024, while for the nine months, it decreased from $0.14 to $0.08 due to higher operating expenses [7][15] Product Sales - ETUARY® generated $27.7 million in sales for Q3 2025, up from $25.3 million in Q3 2024, while Etorel® and Contiva® contributed $1.5 million and $1.2 million, respectively, in their first full quarter of sales [8][16] - The company faced initial supply chain and distribution challenges for Etorel®, which moderated its launch uptake, but demand is starting to improve [17] Pipeline Development - Gyre is advancing its pipeline with a focus on Hydronidone, which is progressing towards NDA submission in China, and plans to file a U.S. IND for MASH-associated liver fibrosis in 2026 [5][14] - The company completed patient enrollment in a 52-week Phase 3 trial of pirfenidone for pneumoconiosis, with plans to initiate an adaptive Phase 2/3 trial for oncology-related pulmonary complications in Q4 2025 [5][14] Cash Position - As of September 30, 2025, Gyre held $80.3 million in cash and cash equivalents, reflecting a 57% increase year-to-date [7][12]